Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone Turnover Markers in Rheumatoid Arthritis Patients Treated With Tofacitinib
2018-003162-13Phase 4Completed
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tofacitinib in rheumatoid arthritis (RA), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Serum levels of bone turnover markers. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2018-003162-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003162-13.